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Background/Aims: The notion that acute hepatitis A super-
imposed on chronic hepatitis B infection leads to a worse out-
come than acute hepatitis A alone remains controversial. The 
aim of this study was to determine the inﬂ  uence of the pres-
ence of hepatitis B surface antigen (HBsAg) on the severity of 
acute hepatitis A. Methods: We retrospectively analyzed 449 
patients hospitalized for acute hepatitis A from January 2000 
to February 2010 and compared clinical outcomes based 
on the presence of HBsAg. Results: Of the 449 patients, 30 
patients were in the HBsAg-positive group and 419 in the 
HBsAg-negative group. The HBsAg-positive group was older 
than the HBsAg-negative group (36.1±8.3 vs 31.8±8.5 years, 
p=0.004); however, other baseline characteristics were simi-
lar between the 2 groups. Mean peak values of prothrombin 
time, serum total bilirubin, and serum creatinine at admis-
sion were significantly higher in the HBsAg-positive group. 
When comparing clinical outcomes between the 2 groups, 
gastrointestinal bleeding, acute renal failure, and acute liver 
failure were more frequently observed in the HBsAg-positive 
group. In particular, the incidence of acute liver failure was 
approximately 9-fold higher in the HBsAg-positive group than 
in the HBsAg-negative group (23.3% vs 3.3%; odds ratio [OR], 
8.80; p<0.001). Multivariate analysis showed that HBsAg 
(OR, 7.43; 95% conﬁ  dence interval [CI], 2.56 to 21.57) and 
age (OR, 1.07; 95% CI, 1.02 to 1.13) were independent risk 
factors for the occurrence of acute liver failure. Conclusions: 
In patients with chronic hepatitis B infection, acute hepatitis 
A is associated with more severe clinical outcomes, including 
acute liver failure, compared with patients with acute hepati-
tis A alone. (Gut Liver 2011;5:500-505)
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INTRODUCTION
The incidence of acute hepatitis A in Korea has been increas-
ing significantly because the rate of seropositivity of anti-
HAV(IgG) has been decreasing with socioeconomic development 
and improvements in public health and environment.
1 In a re-
cent survey, approximately half of Korean individuals infected 
with the hepatitis A virus (HAV) had to be hospitalized with 
acute hepatitis.
2 Most patients with HAV infection have a favor-
able clinical course and spontaneous recovery, and only a few 
suffer from serious complications of acute hepatitis A such as 
acute fulminant hepatitis, acute renal failure, or cholestatic hep-
atitis. In some previous reports, the clinical course and outcome 
of hepatitis A in patients with underlying chronic hepatitis B vi-
rus (HBV) infection was associated with higher peak laboratory 
abnormalities and more severe outcomes, including acute liver 
failure and a higher fatality rate.
3 However, there is controversy 
over the influence of HBV infection on the outcome of acute 
hepatitis. Vaccines have been available against hepatitis B and 
hepatitis A since 1981 and 1995, respectively.
4 Formalin-inacti-
vated hepatitis A vaccination is considered safe and effective in 
patients with chronic liver disease, including chronic hepatitis 
B. Nevertheless, in Korea, an area with endemic HAV and HBV 
infection, hepatitis A has not been designated a mandatory vac-
cination. In addition, there are very few comparative studies 
of clinical outcome in acute hepatitis A according to the pres-
ence of hepatitis B surface antigen (HBsAg). In this study, we 
retrospectively compared the clinical outcome of acute hepatitis 
A between HBsAg-positive and HBsAg-negative patients, and 
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severity of acute hepatitis A.
MATERIALS AND METHODS
1. Patients
Between January 2000 and February 2010, 452 consecutive 
patients who were admitted to Samsung Medical Center, Seoul, 
Korea for acute hepatitis A were retrospectively reviewed. Three 
patients who were positive for hepatitis C virus (HCV) RNA with 
anti-HCV were excluded from this study. A total of 449 patients 
were included and classified into 2 groups: HBsAg-positive 
group (n=30) and HBsAg-negative group (n=419).
2. Methods
Acute hepatitis A was diagnosed when patients were hospital-
ized with typical symptoms of acute viral hepatitis and presence 
of serum IgM anti-HAV (Abbott, HAV Ab-M). The presence of 
IgM anti HAV and HBsAg and the absence of IgM anti-HBc 
established the diagnosis of acute hepatitis A superimposed on 
a chronic HBsAg carrier. We adjusted the data for age, sex, the 
route of virus infection, and comorbidity in both positive-HB-
sAg and negative-HBsAg groups. The following blood tests were 
performed at the initial time of admission and regularly during 
admission: hemoglobin, platelet count, prothrombin time (PT), 
serum aspartate aminotransferase (AST), serum alanine amino-
transferase (ALT), serum total bilirubin, alkaline phosphatase 
(ALP), serum albumin, γ-glutamyl transferase (GGT), and serum 
creatinine. Patients who were HBsAg-positive were compared 
with patients without HBsAg with respect to complete blood 
count at the time of admission and the most severe laboratory 
abnormality of the biochemical profile, including liver function 
tests, at admission. We also compared the incidences of pro-
longed jaundice, gastrointestinal bleeding, acute renal failure, 
acute liver failure, liver transplantation, death, and the mean 
durations of hospitalization between the 2 groups to determine 
the differences in clinical outcome. Postoperative hospital stay 
was included in the estimation of hospitalization time for pa-
tients who underwent liver transplantation. Patients were con-
sidered to have acute liver failure (ALF) according to the widely 
accepted definition of ALF, which includes evidence of coagula-
tion abnormality, usually an international normalized ratio (INR) 
≥1.5, and any degree of mental alteration (encephalopathy) in 
a patient without pre-existing cirrhosis and with an illness of 
<26 weeks duration, with the exception of liver cirrhosis caused 
by vertically-acquired HBV if the disease has been recognized 
for <26 weeks.
5 The definition for acute renal failure (ARF) was 
an increase in serum creatinine concentration ≥0.5 mg/dL or 
by 50% compared with baseline value.
6 Gastrointestinal bleed-
ing was defined as when patients presented with hematemesis, 
melena or hematochezia and had a drop in hemoglobin ≥1.5 g/
dL. This study’s protocol was approved by the Ethics Committee 
of Samsung Medical Center and the study was conducted in ac-
cordance with the principles of the Declaration of Helsinki.
3. Statistical analysis
Statistical analyses were performed using PASW Statistics 
17.0 (SPSS Inc., Chicago, IL, USA). Statistical analyses were per-
formed using the χ
2 test or the Fisher’s exact test for categorical 
variables and the Mann-Whitney test for continuous variables. 
Continuous variables are expressed as mean and standard de-
viations, and dichotomous variables are expressed as simple 
proportions with 95% confidence intervals (CI). p-values of less 
than 0.05 were considered statistically significant.
Table 1. Baseline Characteristics of Patients with Acute Viral Hepati-
tis A
Characteristic
HBsAg(+) 
group
(n=30)
HBsAg(-) 
group
(n=419)
p-value
Age, yr
   Mean±SD 36.1±8.3 31.8±8.5 0.004
   <30   5 (16.7) 175 (41.8) 0.007
   30-39 14 (46.7) 180 (43.0) 0.692
   40-49 10 (33.3)   54 (12.9) 0.002
   ≥50 1 (3.3) 10 (2.4) 0.746
Sex
   Male
   Female 
22 (73.3)
  8 (26.7)
245 (58.5)
174 (41.5)
0.109
Excessive alcohol consumption* 2 (6.7) 29 (6.9) 0.786
Infection source
   Unknown origin 28 (93.3) 398 (95.0) 0.691
   Contact with hepatitis A patient 1 (3.3) 15 (3.6) 0.944
   Intake of contaminated foods 1 (3.3)  6 (1.4) 0.417
Clinical findings and symptoms on admission
   Jaundice 25 (83.3) 347 (82.8) 0.942
   Nausea/vomiting 24 (80.0) 359 (85.7) 0.396
   Anorexia 22 (73.3) 315 (75.2) 0.821
   Fever 16 (53.3) 248 (59.2) 0.529
   General weakness 23 (90.0) 324 (77.3) 0.934
   Abdominal pain 17 (40.6) 181 (43.2) 0.151
Underlying diseases
   Diabetes mellitus 1 (3.3)   9 (2.1) 0.671
   Hypertension 2 (6.7) 12 (2.8) 0.247
   Chronic kidney disease 0 (0.0)   2 (0.2)
   Malignancy 0 (0.0)   4 (1.0)
   Others
̈ 1 (3.3) 12 (2.7) 0.882
   Total   4 (13.0) 39 (9.3) 0.469
Data are presented as mean±SD or number (%).
*Alcoholic intake >40 g/day; 
̈Thyroid disease, asthma, epilepsy, pul-
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RESULTS
1. Clinical characteristics
Basic characteristics of the 449 patients are shown in Table 1. 
Among the 30 patients in the HBsAg-positive group, the males 
outnumbered the females 22 (73.3%) to 8 (26.7%). Mean age 
at the time of admission was 36.1 years and 31.8 years in the 
HBsAg-positive group and HBsAg-negative group, respectively, 
and the HBsAg-positive group was significantly older than the 
HBsAg-negative group (p=0.004). In both HBsAg-positive and 
HBsAg-negative groups, the majority of patients were in the 
age group of 30 to 39 years. The infection source of acute hepa-
titis A was almost exclusively unknown origin in both groups 
(93.3% in the positive group vs 95.0% in the negative group). 
Two patients in the HBsAg-positive group had liver cirrhosis 
at the time of admission for acute hepatitis A: one patient had 
been diagnosed with Child-Pugh class B liver cirrhosis 1 year 
previously, and the other patient was newly diagnosed with 
Child-Pugh class A liver cirrhosis. Seven patients of the HBsAg-
positive group were HBeAg-positive and 5 of these had received 
antiviral drugs such as lamivudine for chronic hepatitis B. Of 30 
patients with acute hepatitis A and chronic HBV infection, HBV 
DNA was detectable in 20 patients at the time of admission. 
From 2000 to 2005, the detection rate for HBV DNA was lower 
than in the 5 years since 2006 (42.9% vs 73.9%), primarily be-
cause HBV DNA has been measured in International Units (IU) 
using highly sensitive reverse transcription-polymerase chain 
reaction since 2006, whereas between 2000 and 2005, HBV 
DNA was measured in picograms by a hybrid capture method 
with a lower limit of detection of 0.5 pg/mL.
2. Laboratory ﬁ  ndings 
We compared the initial values for hemoglobin level and 
platelet count at the time of admission, and the most severe val-
ue of PT, serum albumin, AST, ALT, and serum total bilirubin, 
which are directly correlated to liver function, during admission 
between the 2 groups of patients with acute hepatitis A (Table 
2). Mean platelet count at the time of admission was signifi-
cantly lower in patients of the HBsAg-positive group compared 
with the HBsAg-negative group (137±69 vs 177±84×10
3/mm
3, 
p=0.006). Mean peak values of PT (2.8±2.3 vs 1.7±1.9 INR, 
p=0.016), serum total bilirubin (19.9±17.6 vs 11.1±9.3 mg/
dL, p<0.001) and serum creatinine (2.1±2.1 vs 1.5±2.2 mg/dL, 
p<0.001) during admission were also significantly higher in pa-
tients of the HBsAg-positive group. In contrast, the mean values 
of hemoglobin, serum albumin, AST, ALT, GGT, and serum cre-
atinine did not differ significantly between the HBsAg-positive 
and HBsAg negative groups.
3. Clinical outcomes
To evaluate the influence of chronic HBV infection on the 
severity of acute hepatitis A, the incidences of prolonged jaun-
dice, gastrointestinal bleeding, ARF, ALF, liver transplantation, 
death, and the mean durations of hospitalization were compared 
in terms of clinical outcomes between the 2 groups (Table 3). Of 
the 30 patients who were carriers of HBsAg, 7 developed ALF. 
Two of these patients had been taking lamivudine, and the other 
5, including 1 patient newly diagnosed with Child-Pugh class A 
liver cirrhosis, had not received prior treatment. All 7 patients 
had detectable HBV DNA at the time of admission. HBV DNA 
level of 7 patients at the time of admission were varied from 65 
to 45,919 IU/mL. Two patients who had been taking lamivudine 
had maintained viral suppression (HBV DNA levels <2,000 IU/
mL). However, 1 of 2 patients showed viral reactivation of HBV 
replication, which was characterized by HBV DNA levels >2,000 
IU/mL, at the time of admission. One of the 2 patients with liver 
cirrhosis, who had been diagnosed with Child-Pugh class B liver 
cirrhosis 1 year previously, had a favorable clinical course and 
spontaneous recovery. The incidence of ALF was significantly 
higher among patients with acute hepatitis A and chronic HBV 
infection than among patients with acute hepatitis A alone 
(23.3% vs 3.3%; odds ratio [OR], 8.80; p<0.001). Among the to-
tal 449 patients with acute hepatitis A, 21 patients had ALF, 11 
patients underwent liver transplantation, and 4 died secondary 
to ALF. Among the 10 ALF patients who did not undergo liver 
transplantation, 2 patients in deep coma died before a donor 
liver could be found, whereas the other 8 patients recovered 
spontaneously. Two patients with ALF died in the postoperative 
period after undergoing liver transplantation. One patient died 
due to vascular compression caused by huge hematoma around 
the transplanted liver, and the other died due to primary graft 
Table 2. Laboratory Parameters of Patients with Acute Viral Hepatitis 
A during Admission
Parameter
HBsAg(+) 
group
(n=30)
HBsAg(-) 
group
(n=419)
p-value
Hb, g/dL* 14.7±1.9 14.6±1.9 0.895
Platelet count, ×10
3/mm
3* 137±69 177±84 0.006
PT (INR)
̈ 2.8±2.3 1.7±1.9 0.016
Serum albumin, g/dL
̈ 3.0±1.0 3.3±0.5 0.119
AST, IU/L
̈ 3,747±5,108 2,874±2,997 0.494
ALT, IU/L
̈ 2,603±2,230 3,120±2,075 0.107
Serum total billirubin, mg/dL
̈ 19.9±17.6 11.1±9.3 <0.001
ALP, IU/L
̈ 244±366 217±85 0.080
GGT, IU/L
̈ 281±224 312±215 0.233
Serum creatinine, mg/dL
̈ 2.1±2.1 1.5±2.2 <0.001
Data are presented as mean±SD.
HBsAg, hepatitis B surface antigen; Hb, hemoglobin; PT (INR), pro-
thrombin time (international normalized ratio); AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; ALP, alkaline phospha-
tase; GGT, γ-glutamyl transferase.
*Initial value at the time of admission; 
̈Most severe value at admis-
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nonfunction. ARF was noted in 46 of 449 patients with acute 
hepatitis A. With 2 of the deaths from hepatitis A occurring in 
patients with chronic HBV infection, the case fatality rate in this 
subset of patients was 6.7%. One of these patients had died after 
receiving a liver transplant. Among the 46 patients with ARF, 8 
were in the HBsAg-positive group and 38 were in the HBsAg-
negative group. The incidence of ARF in patients with acute 
hepatitis A and chronic HBV infection was also significantly 
higher than in patients with acute hepatitis A alone (OR, 3.64; 
p=0.007). In comparison of hospitalization time according to 
the presence of HBsAg, the average duration of hospitalization 
for the HBsAg-positive and -negative groups was 21.6±4.1 days 
and 10.0±0.4 days, respectively. Thus, the hospitalization time 
reflecting the morbidity caused by acute hepatitis A was signifi-
cantly longer in the HBsAg-positive group than in the HBsAg-
negative group (p=0.007). 
To evaluate the potential risk characteristics of acute hepatitis 
A-associated ALF, we performed multivariate analysis. Table 4 
shows odds ratios for the incidence of ALF associated with acute 
hepatitis A based on covariates that include age, sex, HBsAg, 
comorbidity, and excessive alcohol consumption. Logistic re-
gression analysis showed that HBsAg positivity (OR, 7.43; 95% 
confidence interval [CI], 2.56 to 21.57) and age (OR, 1.07; 95% 
CI, 1.02 to 1.13) were independent predictors for the occurrence 
of ALF. Other factors such as sex, comorbidity, and excessive 
alcohol consumption were not significant.
DISCUSSION
ALF is a rare complication of HAV infection. Fulminant 
hepatitis in HAV infection occurs in approximately 0.1% to 
0.5% of cases.
7 HAV infections in the Korean adult population 
have been increasing considerably due to the decreased oppor-
tunity for HAV infection in younger individuals.
8 As a result, a 
higher frequency of clinically severe hepatitis, including ALF, 
has been observed. In addition, the increase in HAV infection in 
adults has resulted in a relative increase in the number of cases 
of acute hepatitis A among HBsAg carriers. HAV-related liver 
disease is known to be caused by immunologic mechanisms 
rather than direct toxicity of the virus.
9 INF-γ produced by 
HAV-specific T cells may play an important role in the patho-
genesis of infection.
10 During infection with HAV and HBV, it is 
possible that INF-γ produced in response to HAV stimulus has 
an antiviral effect on HBV infection. It has also been reported 
that HAV superinfection in patients with chronic hepatitis B 
suppresses hepatitis B viral replication.
11-13 However, because a 
reduction in HBV viral load is associated with an increase in the 
immune response of the host, in some cases an excessive host 
response may induce severe damage of hepatocytes. Although 
their study was not on hepatitis B, Cacopardo et al.
14 suggested 
Table 3. Clinical Outcomes of Patients with Acute Viral Hepatitis A
Clinical outcome
HBsAg(+) group
(n=30)
HBsAg(-) group
(n=419)
OR
(95% CI)
p-value
Prolonged jaundice* 4 (13.3) 27 (6.4) 2.23 (0.73-6.86) 0.143
Gastrointestinal bleeding 2 (6.7)   3 (0.7)   9.91 (1.59-61.72) 0.038
Acute renal failure 8 (26.7) 38 (9.1) 3.64 (1.52-8.75) 0.007
Acute liver failure 7 (23.3) 14 (3.3)   8.80 (3.24-23.93) <0.001
Liver transplantation 5 (16.7)   6 (1.4) 13.77 (3.93-48.22) <0.001
Death 2 (6.7)   2 (0.5) 14.89 (2.02-109.7) 0.024
Hospitalization time, mean days±SD 21.6±4.1 10.0±0.4 0.007
Data are presented as mean±SD or number (%).
HBsAg, hepatitis B surface antigen; OR, odds ratio; CI, confidence interval.
*Serum total bilirubin level did not normalize within 3 months. 
Table 4. Multiple Logistic Regression Analysis of Prognostic Factors for Acute Liver Failure
Covariate
Univariate 
OR (95% CI)
p-value
Multivariate
OR (95% CI)
p-value
Age, yr 1.08 (1.03-1.13) 0.001 1.07 (1.02-1.13) 0.006
Sex, M/F 0.91 (0.37-2.19) 0.824 0.61 (0.23-1.66) 0.334
HBsAg-positive   8.80 (3.24-23.93) 0.000   7.43 (2.56-21.57) <0.001
Underlying disease 3.21 (1.11-9.30) 0.031 2.54 (0.80-8.03) 0.113
Excessive alcohol consumption 2.38 (0.66-8.57) 0.184   2.73 (0.67-11.07) 0.161
OR, odds ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen.504  Gut and Liver, Vol. 5, No. 4, December 2011
that HAV and HCV-related liver cell damage and viral clearance 
might be mediated by HAV-specific T cell responses with en-
hanced production of INF-γ. Several studies have reported that 
HAV superinfection in patients with pre-existing liver disease is 
associated with a high rate of morbidity and mortality.
15-19 How-
ever, not all reported studies are consistent with this view. Some 
reports have indicated that new HAV infections in patients with 
chronic viral hepatitis showed no hepatic decompensation and 
were similar to those of patients with hepatitis A alone.
20-22 Re-
garding superinfection with HAV in patients with hepatitis B vi-
rus, the clinical implications are more controversial. The largest 
case series reported an outbreak of hepatitis A in Shanghai in 
1988,
18 in which 310,746 cases were reported with a fatality rate 
of 0.015%. When the number of HBsAg-positive cases was cal-
culated from an assumed 8.8% HBsAg carrier rate in this region 
of China, the case fatality rate was 6.2-fold greater in chronic 
HBsAg carriers (15 deaths among 27,346 patients, 0.05%) than 
in patients without HBV infection (25 deaths among 283,400 
patients, 0.009%). An analysis of cases of acute hepatitis A in 
the United States from 1983 through 1998 reported an overall 
case fatality rate of 0.33% (381 deaths/115,551 patients), with 
a much higher percentage of mortality (27 deaths/231 patients, 
11.7%) in chronic HBsAg carriers; thus the case fatality rate of 
acute hepatitis A in HBsAg carriers was 58.5-fold higher than 
in patients who were not HBsAg carriers.
16 In recent years, two 
studies have investigated the influence of acute HAV superin-
fection in Taiwan and Thailand, areas with endemic HAV and 
HBV infection. Chu and Liaw
15 reported that HBsAg carriers 
were at a nine-fold increased risk of fulminant hepatitis com-
pared with non-carriers, and Pramoolsinsap
17 reported that ful-
minant or submassive hepatitis occurred in 10 of 20 (55%) HB-
sAg carriers and in 4 of 12 (33%) patients with HBV- or HCV-
related chronic liver disease.
In contrast to the above reports, other reports have shown 
an uncomplicated course of acute hepatitis A in patients with 
chronic hepatitis B. For example, Tassopoulos and Papaevan-
gelou
21 found no case of fulminant hepatitis among 10 HBsAg 
carriers with acute hepatitis A and suggested that HAV superin-
fection of HBsAg carriers did not adversely influence the course 
of chronic hepatitis B. Similarly, Vento et al.
23 revealed that, un-
like patients with chronic hepatitis C, most patients with chronic 
hepatitis B who acquired HAV infections had uncomplicated 
courses. In addition, no cases of fulminant hepatitis or death 
were observed in a retrospective study of 177 Korean patients 
with acute hepatitis A, including 10 HBsAg-positive patients.
24 
In our study, there were higher prevalences of ALF, emergen-
cy liver transplantation for ALF, and ARF among the patients 
with acute HAV superimposed on chronic HBV infection, and 
our data also showed that these patients were associated with 
higher peak laboratory abnormalities and longer hospital stays. 
The present study confirmed previous findings that acute HAV 
infection could cause severe liver injury in patients with chronic 
HBV infection. Whether the presence of HBsAg itself has a neg-
ative effect on clinical outcomes of acute hepatitis A is open to 
dispute. Several studies suggest that the severity of acute hepa-
titis A is correlated to the severity of the underlying chronic 
HBV infection since the risk from hepatitis A is increased in the 
presence of chronic hepatitis or liver cirrhosis, compared with 
healthy HBsAg carriers.
9,25 This explanation of the conflicting 
influence of chronic hepatitis B infection on clinical features 
of acute hepatitis A has become the commonly accepted view. 
However, in the majority of cases it is hard to determine the 
state of the HBsAg carrier (for example healthy carrier, chronic 
hepatitis, or liver cirrhosis) at the time of treatment for acute 
hepatitis A, because in most cases the state of their liver has 
not been regularly checked. In our study, only seven HBsAg-
positive patients, including five patients who had been treated 
for chronic hepatitis B, had been followed up with their doctors. 
Therefore, we are not convinced that there is no substantial 
risk of fulminant hepatitis in healthy HBsAg carriers. In Korea, 
an area with a high prevalence of HBV infection, a progressive 
decrease in natural immunity against HAV has been observed. 
Moreover, the seroprevalance of HAV infection in patients with 
chronic liver disease is similar to that in the general population 
classified by age.
26,27 Therefore we suggest that individuals with 
chronic HBV infection should be considered as candidates for 
anti-HAV vaccination, especially as the HAV vaccine is known 
to be equally safe in patients with chronic liver diseases and the 
general population.
28
In conclusion, our study indicates that acute hepatitis A su-
perimposed on chronic HBV infection is associated with serious 
morbidity and mortality. Especially in terms of ALF, HBsAg-
positive patients with acute hepatitis A are at an approximately 
nine-fold increased risk. Increasing age is known to be related 
to increased HAV morbidity and mortality, as well as underly-
ing liver disease. Indeed, in our study the incidence of ALF was 
significantly associated with advanced age; however, when we 
performed multiple regression analysis the statistical signifi-
cance of age was reduced compared with the significance of the 
presence of HBsAg. The main shortcomings of the present study 
are its retrospective nature and the fact that the study was con-
ducted in a tertiary referral hospital, therefore there may be se-
lection bias for patients who were referred for intensive care or 
liver transplantation. In other words, there may be a possibility 
that when patients with acute HAV infection were expected to 
have a poor prognosis, these patients were likely to be referred 
to specialty hospital for liver transplantation. Despite these, our 
study is significant in the sense that it is one of few analyses on 
the difference in clinical features between HBsAg-positive and 
HBsAg-negative patients in this HBV endemic area. Further-
more, the results of this study also indicate that acute hepatitis 
A is no longer a mild disease, at least in HBsAg carriers.Kim KM, et al: Clinical Features of Hepatitis A in HBsAg-Positive Patients  505
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